Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1888-1894

  Hogan, Vanessa E ^a   Holweg, Cécile T J ^b   Choy, David F ^b   Kummerfeld, Sarah K ^b   Hackney, Jason A ^b   Teng, Y K Onno ^c   Townsend, Michael J ^b   Van Laar, Jacob M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b GENENTECH INC   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; DISEASE ACTIVITY; DOWN REGULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; KNEE ARTHROSCOPY; MACROPHAGE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RNA ISOLATION; SCORING SYSTEM; SYNOVIUM; T LYMPHOCYTE; TREATMENT RESPONSE;

ACETAMINOPHEN; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLEMASTINE; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84867398434     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201115     Document Type: Article

References (22)

1. Manzo A, Bombardieri M, Humby F, et al. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010;233:267-85.
2. Gutierrez-Roelens I, Galant C, Theate I, et al. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheum 2011;63:1246-54.
3. Bansard C, Lequerré T, Derambure C, et al. Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra). Rheumatology (Oxford) 2011;50:283-92.
4. van Baarsen LG, Wijbrandts CA, Timmer TC, et al. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 2010;62:1602-7.
5. Lindberg J, Wijbrandts CA, van Baarsen LG, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS ONE 2010;5:e11310.
6. van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003;48:2132-45. (Pubitemid 36959193)
7. Badot V, Galant C, Nzeusseu Toukap A, et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009;11:R57.
8. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, et al. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 2003;4:187-96. (Pubitemid 38967596)
9. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
10. Hahne F. Bioconductor case studies. New York, NY: Springer 2008.
11. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18. (Pubitemid 350262317)
12. van Oosterhout M, Bajema I, Levarht EW, et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 2008;58:53-60.
13. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8. (Pubitemid 46399424)
14. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25. (Pubitemid 351956651)
15. Yeo L, Toellner KM, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011;70:2022-8.
16. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8. (Pubitemid 30395732)
17. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908. (Pubitemid 350262316)
18. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14. (Pubitemid 47122311)
19. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010;62:3607-14.
20. Vosslamber S, Raterman HG, van der Pouw Kraan TC, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011;70:1153-9.
21. Kraan MC, Reece RJ, Smeets TJ, et al. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
22. Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med 2011;12:229-36.